Article
Medicine, General & Internal
Xiaojian Qin, Dongmei Ji, Weijie Gu, Weiqing Han, Hong Luo, Chuanjun Du, Qing Zou, Zhongquan Sun, Chaohong He, Shaoxing Zhu, Tie Chong, Xin Yao, Ben Wan, Xinfeng Yang, Aobing Bai, Chunlei Jin, Jianjun Zou, Dingwei Ye
Summary: This study evaluated the safety, pharmacokinetics, and activity of the novel AR antagonist SHR3680 in patients with metastatic CRPC. The results showed that SHR3680 was well tolerated and had promising anti-tumor activity across all doses. A daily dose of 240 mg was recommended for further phase 3 study.
Article
Oncology
David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud, Anthony M. Joshua, Jose Luis Perez-Gracia, Casilda Llacer Perez, Sang Joon Shin, Bruno Fang, Minal Barve, Marco Maruzzo, Sergio Bracarda, Miso Kim, Yannick Kerloeguen, Jorge Daniel Gallo, Sophia L. Maund, Adam Harris, Kuan-Chieh Huang, Victor Poon, Dhruvitkumar S. Sutaria, Howard Gurney
Summary: The combination of ipatasertib and rucaparib showed manageable safety in patients with metastatic castration-resistant prostate cancer, but did not demonstrate synergistic or additive antitumor activity in previously treated patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Aurelius Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher-Senn, Stefan A. J. Buck, Ron H. J. Mathijssen, Ulrich Jaehde, Silke Gillessen, Markus Joerger
Summary: This study compares the efficacy of cabazitaxel at different doses in patients with metastatic castration-resistant prostate cancer (mCRPC) and finds that individual dose adjustments of cabazitaxel can improve clinical feasibility and survival outcome in patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Anthony Serritella, Daniel Shevrin, Elisabeth Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz
Summary: This study evaluated the effectiveness of dual androgen receptor (AR) and glucocorticoid receptor (GR) antagonism in castration-resistant prostate cancer (CRPC). The combination of enzalutamide and mifepristone was found to be safe and well-tolerated, but did not meet the primary endpoint. Further research should explore the use of more specific GR antagonists combined with AR antagonists in earlier disease stages.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Maria Jose Juan Fita, Urbano Anido Herranz, Maria Jose Mendez-Vidal, Regina Girones-Sarrio, Jose Munoz-Langa, Juan Sepulveda-Sanchez, Begona Mellado, Carlos Alvarez-Fernandez, Lucia Heras Lopez, Jose Antonio Lopez-Guerrero, Zaida Garcia-Casado, Ana Calatrava, Miguel angel Climent
Summary: In this study, the efficacy of maintenance treatment with olaparib in metastatic castration-resistant prostate cancer patients was examined. The results demonstrate that olaparib can stabilize the disease and prolong the progression time for patients with specific gene mutations.
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Gilberto Filaci, Daniela Fenoglio, Franco Nole, Elisa Zanardi, Laura Tomasello, Massimo Aglietta, Gianluca Del Conte, Joan Carles, Rafael Morales-Barrera, Pamela Guglielmini, Giorgio Scagliotti, Alessio Signori, Alessia Parodi, Francesca Kalli, Giuseppina Astone, Francesca Ferrera, Tiziana Altosole, Giuseppina Lamperti, Domenico Criscuolo, Francesco Gianese, Francesco Boccardo
Summary: This study aimed to compare the safety and immunological response of three GX301 regimens in metastatic castration-resistant prostate cancer patients who had response/disease stability after docetaxel chemotherapy. Results showed that the rate of immunological responders was proportionally related to the number of immunizations, suggesting that regimens with a higher number of administrations may lead to better immunological outcomes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Bobby C. Liaw, Che-Kai Tsao, Sonia Seng, Tomi Jun, Yixuan Gong, Matthew D. Galsky, William K. Oh
Summary: This study evaluated the feasibility and usefulness of blood-based biomarkers to identify platinum-sensitive mCRPC. Although some biomarkers were assessed, none were significantly associated with response to satraplatin.
Article
Oncology
Eric Feng, Nicholas R. Rydzewski, Meng Zhang, Arian Lundberg, Matthew Bootsma, Kyle T. Helzer, Joshua M. Lang, Rahul Aggarwal, Eric J. Small, David A. Quigley, Martin Sjostrom, Shuang G. Zhao
Summary: In this study, the researchers identified the intrinsic molecular subtypes of metastatic castration-resistant prostate cancer (mCRPC) and assessed their molecular and clinical correlates using a large cohort with gene expression data. The results showed the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, emphasizing the need for transcriptome-wide profiling in future studies to understand the impact of these differences on treatment responses and outcomes.
CLINICAL CANCER RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Summary: Lu-177-PSMA therapy shows promising clinical efficacy in patients with mCRPC, with predictors of efficacy being significant. Ongoing clinical trials, including a phase III multicenter FDA registration trial, are currently being conducted in the United States.
Article
Oncology
Susan F. Slovin, Karen Knudsen, Susan Halabi, Renee de Leeuw, Ayesha Shafi, Praneet Kang, Steven Wolf, Bin Luo, Anuradha Gopalan, Tracy Curley, Mark Fleming, Ana Molina, Celina Fernandez, Kevin Kelly
Summary: Upfront combination therapy in chemotherapy/ARSI-naive mCRPC patients showed improved radiographic progression-free survival and may benefit some men, but further research is needed to identify the specific population that would benefit from this treatment.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Kristine Kreis, Dirk Horenkamp-Sonntag, Udo Schneider, Jan Zeidler, Gerd Glaeske, Lothar Weissbach
Summary: This study examined real-world haematological toxicity, overall survival, and treatment characteristics of docetaxel and cabazitaxel chemotherapy in mCRPC patients. The findings suggest that cabazitaxel treatment poses higher risk of haematological toxicities and shorter survival time, emphasizing the importance of strict indications when using cabazitaxel in mCRPC patients.
Article
Oncology
Kim N. Chi, Dana Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea J. Pereira De Santana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Zurawski, Valerii Sakalo, Gary E. Mason, Peter Francis, George Wang Ms, Daphne Wu, Brooke Diorio, Angela Lopez-Gitlitz, Shahneen Sandhu
Summary: This study investigated the efficacy of niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC and HRR gene alterations. The results showed that the combination therapy significantly prolonged radiographic progression-free survival compared to abiraterone acetate plus prednisone alone. The treatment was well tolerated with manageable adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Hideaki Miyake, Yasumasa Kakei, Yuzo Nakano, Tomoaki Terakawa, Keiko Miyakoda, Kenichi Harada, Masato Fujisawa
Summary: This multicentre, open-label, single-arm clinical trial aims to evaluate the efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer. The trial is conducted at multiple hospitals in Japan, with a target of 110 patients. The primary outcome is the prostate-specific antigen (PSA) response rate, with secondary outcomes including time to PSA progression, survival rates, and adverse events. The study has been approved ethically and the findings will be disseminated through conferences and publications.
Article
Oncology
Catherine H. Marshall, Wei Fu, Hao Wang, Jong Chul Park, Theodore L. DeWeese, Phuoc T. Tran, Daniel Y. Song, Serina King, Michaella Afful, Julia Hurrelbrink, Charlotte Manogue, Patrick Cotogno, Nancy P. Moldawer, Pedro C. Barata, Charles G. Drake, Edwin M. Posadas, Andrew J. Armstrong, Oliver Sartor, Emmanuel S. Antonarakis
Summary: The study aimed to investigate whether radium-223 enhances peripheral immune responses to sipuleucel-T in men with bone-predominant, minimally symptomatic metastatic castration-resistant prostate cancer. Results showed that patients receiving the combination treatment of sipuleucel-T and radium-223 were more likely to experience a PSA decline, as well as longer progression-free survival and overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Marie Lange, Natacha Heutte, Sabine Noal, Olivier Rigal, Jean-Emmanuel Kurtz, Christelle Levy, Djelila Allouache, Chantal Rieux, Johan Lefel, Benedicte Clarisse, Alexandra Leconte, Corinne Veyret, Philippe Barthelemy, Nadine Longato, Laure Tron, Helene Castel, Francis Eustache, Benedicte Giffard, Florence Joly
Article
Oncology
Audrey Rambeau, Berengere Beauplet, Heidi Laviec, Idlir Licaj, Alexandra Leconte, Claire Chatel, Priscille Le Bon, Julie Denhaerynck, Benedicte Clarisse, Nicole Frenkiel, Marie Lange, Florence Joly
JOURNAL OF GERIATRIC ONCOLOGY
(2019)
Article
Neurosciences
Florent Laferriere, Zuzanna Maniecka, Manuela Perez-Berlanga, Marian Hruska-Plochan, Larissa Gilhespy, Eva-Maria Hock, Ulrich Wagner, Tariq Afroz, Paul J. Boersema, Gery Barmettler, Sandrine C. Foti, Yasmine T. Asi, Adrian M. Isaacs, Ashraf Al-Amoudi, Amanda Lewis, Henning Stahlberg, John Ravits, Francesca De Giorgi, Francois Ichas, Erwan Bezard, Paola Picotti, Tammaryn Lashley, Magdalini Polymenidou
NATURE NEUROSCIENCE
(2019)
Article
Oncology
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, Olivier Mir, Nicolas Penel, Nicolas Isambert, Florence Duffaud, Emmanuelle Bompas, Thomas Esnaud, Romain Boidot, Damien Geneste, Francois Ghiringhelli, Carlo Lucchesi, Carine A. Bellera, Francois Le Loarer, Antoine Italiano
CLINICAL CANCER RESEARCH
(2019)
Article
Clinical Neurology
Zhenwei Yu, Min Shi, Tessandra Stewart, Pierre-Olivier Fernagut, Yang Huang, Chen Tian, Benjamin Dehay, Anzari Atik, Dishun Yang, Francesca De Giorgi, Francois Ichas, Marie-Helene Canron, Roberto Ceravolo, Daniela Frosini, Han-Joon Kim, Tao Feng, Wassilios G. Meissner, Jing Zhang
Article
Multidisciplinary Sciences
Francesca De Giorgi, Florent Laferriere, Federica Zinghirino, Emilie Faggiani, Alons Lends, Mathilde Bertoni, Xuan Yu, Axelle Grelard, Estelle Morvan, Birgit Habenstein, Nathalie Dutheil, Evelyne Doudnikoff, Jonathan Daniel, Stephane Claverol, Chuan Qin, Antoine Loquet, Erwan Bezard, Francois Ichas
Article
Biochemistry & Molecular Biology
Francesca Guarino, Federica Zinghirino, Lia Mela, Xena Giada Pappalardo, Francois Ichas, Vito De Pinto, Angela Messina
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
(2020)
Article
Oncology
Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, Carlos Gomez-Roca, Jean-Philippe Metges, Antoine Adenis, Simon Pernot, Carine Bellera, Michele Kind, Celine Auzanneau, Francois Le Loarer, Isabelle Soubeyran, Alban Bessede, Antoine Italiano
Summary: This study demonstrated that the combination of Regorafenib + avelumab has a synergistic effect in a subset of colorectal cancer patients, mobilizing antitumor immunity. Additionally, computational pathology through quantification of immune cell infiltration may improve patient selection for further studies investigating this approach.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Robbert S. Puijk, Muneeb Ahmerh, S. Nahunz Goldberg, Margin K. Meijerink
Summary: This article proposes standardized definitions for oncologic outcome measures, aiming to uniformly document, analyze, and report outcomes to improve reproducibility, allow for accurate comparisons, and avoid misinterpretations in the field of interventional oncology research. The consensus document was developed by an international panel of experts, focusing on when to assess outcomes, definitions of starting and ending time, survival time, and time-to-event end points.
Article
Oncology
Nadia Oubaya, Pierre Soubeyran, Nicoleta Reinald, Marianne Fonck, Mylene Allain, Sonia Zebachi, Damien Heitz, Marie Laurent, Cecile Delattre, Philippe Caillet, Jerome Dauba, Sylvie Bastuji-Garin, Gilles Albrand, Michael Bringuier, Muriel Rainfray, Etienne Brain, Thomas Grellety, Elena Paillaud, Simone Mathoulin-Pelissier, Carine Bellera, Florence Canoui-Poitrine
Summary: The prognostic assessment of older cancer patients is complicated by their heterogeneity, and routine inflammatory biomarkers play an important role in prognosis assessment. The study found that GPS and CRP/albumin ratio were independently associated with mortality and increased discriminative power. Routine inflammatory biomarkers in older cancer patients add prognostic value to clinical factors.
Article
Oncology
Adolfo Gonzalez Serrano, Marie Laurent, Thomas Barnay, Claudia Martinez-Tapia, Etienne Audureau, Pascaline Boudou-Rouquette, Thomas Aparicio, Florence Rollot-Trad, Pierre Soubeyran, Carine Bellera, Philippe Caillet, Elena Paillaud, Florence Canoui-Poitrine
Summary: Frailty screening can help identify unfit patients in need of geriatric assessment and avoid unnecessary assessment in fit patients. However, the accuracy of screening tests and their clinical benefits have not been confirmed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
James Miles, Isabelle Soubeyran, Florence Marliot, Nicolas Pangon, Antoine Italiano, Carine Bellera, Stephen G. Ward, Franck Pages, Jean Palussiere, Banafshe Larijani
Summary: Radiofrequency ablation (RFA) for the treatment of pulmonary metastases may stimulate an immune response in the remaining tumors. Immune checkpoint interactions may limit this response. A imaging platform that quantifies checkpoint interactions can enhance treatment response in metastatic patients.
Article
Oncology
Serge Evrard, Carine Bellera, Gregoire Desolneux, Coralie Cantarel, Emilie Toulza, Jean-Luc Faucheron, Michel Rivoire, Aurelien Dupre, Jean-Yves Mabrut, Laurent Bresler, Frederic Marchal, Damien Bouriez, Eric Rullier
Summary: The two multicenter single-arm phase II trials showed that delayed colo-anal anastomosis (DCAA) has low rates of anastomotic leakage requiring a diverting ileostomy and acceptable long-term functional results.
Article
Oncology
Paul Sargos, Eberhard Stoeckle, Anne Ducassou, Antoine Giraud, Augustin Mervoyer, Antoine Italiano, Sabrina Albert, Gwenael Ferron, Carine Bellera, Guy Kantor
Summary: This study evaluated the efficacy and feasibility of high-dose intensity-modulated radiotherapy in patients with retroperitoneal liposarcomas. The results showed significant toxicity and rates of second cancers associated with this treatment regimen. Therefore, the optimal indication of radiotherapy for patients with retroperitoneal liposarcomas still needs to be determined.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Cell Biology
Florent Laferriere, Xin He, Federica Zinghirino, Evelyne Doudnikoff, Emilie Faggiani, Wassilios G. Meissner, Erwan Bezard, Francesca De Giorgi, Francois Ichas